David Gandara

David Gandara, Professor of Medicine Emeritus at the University of California, Davis. He is the co-director of the Center for Experimental Therapeutics and Senior Advisor to the Director at UC Davis Comprehensive Cancer Center. He was recently appointed Adjunct Clinical Professor, Translational and Clinical Research Program at the University of Hawaii Cancer Center and Chief Medical Officer for International Society of Liquid Biopsy (ISLB), a non-profit organization dedicated to advancing the science and clinical application of liquid biopsy in cancer diagnosis and therapy. He is an internationally known clinician-scientist and lung cancer thought leader and has published over 450 peer-reviewed papers. He has led many notable research projects in lung cancer, including early therapeutics trials through an N01-sponsored award, cooperative group trials as past-chair of the SWOG Lung Committee and multi-institutional translational science projects such as clinical director of the patient-derived xenograft (PDX) lung program in collaboration with The Jackson Laboratory Cancer Center. Dr. Gandara has been selected for many awards and honors, including the lifetime Scientific Award from the International Association for Study of Lung Cancer (IASLC), the Team Science Award from the Addario Lung Cancer Foundation, and the Trajectory Achievement Award from the ISLB. He is current principal investigator for a National Cancer Institute UG1 award to UCDCCC for cancer clinical trials, co-leader of Lung MAP, a unique NCI-sponsored public-private partnership for new drug development in lung cancer and is founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). Dr. Gandara is past Editor-in-Chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of ASCO. In 2017, Gandara received the Giants of Cancer Care Award in lung cancer.